Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Clin Pharmacol Ther ; 86(1): 92-6, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19387436

ABSTRACT

Gene expression signatures can be developed as comprehensive pathway readouts and used as pharmacodynamic or patient-stratification biomarkers. While a consensus on the best practices for selecting gene expression signatures from microarray data is evolving, we have developed basic guidelines to ensure consistency and quality. Here we illustrate these guidelines through the identification of a growth factor gene expression signature that is responsive to phosphatidylinositol 3-kinase (PI3K) pathway perturbations in vitro and related to phosphatase and tensin homolog (PTEN) deregulation in vivo.


Subject(s)
Biomarkers/metabolism , Gene Expression Regulation/physiology , Intercellular Signaling Peptides and Proteins/genetics , PTEN Phosphohydrolase/genetics , Cell Line, Tumor , Gene Expression Profiling , Genetic Markers/physiology , Humans , Intercellular Signaling Peptides and Proteins/biosynthesis , Intercellular Signaling Peptides and Proteins/physiology , Oligonucleotide Array Sequence Analysis , PTEN Phosphohydrolase/biosynthesis , PTEN Phosphohydrolase/physiology , Phosphatidylinositol 3-Kinases/genetics , Phosphatidylinositol 3-Kinases/metabolism , Signal Transduction/genetics
2.
Eur Respir J ; 32(6): 1451-7, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18799503

ABSTRACT

The balance between inflammatory and repair processes is important in maintaining lung homeostasis in chronic obstructive pulmonary disease (COPD). The aim of the present study was to determine whether or not an integrated index of a biomarker involved in inflammation, C-reactive protein (CRP), and another involved in wound repair, fibronectin, may be a good measure to predict clinical outcomes in COPD. Circulating blood levels of CRP and fibronectin were measured in 4,787 individuals with mild-to-moderate COPD who were prospectively followed for >7 yrs after blood collection as part of the Lung Health Study. To assess the balance between repair and inflammation, a simple ratio was calculated by dividing fibronectin levels by CRP levels and a Cox proportional hazards model was used to determine the relationship between this ratio and all-cause and disease-specific causes of mortality. The relationship between the fibronectin to CRP ratio and all-cause mortality was L-shaped. There was an exponential decay in the adjusted hazard function (i.e. the risk of mortality) as the ratio decreased until a value of 148 was reached, beyond which point the hazard function did not change significantly. Similar results were observed for the risk of coronary and cardiovascular mortality. Circulating fibronectin to CRP ratio is significantly associated with all-cause mortality of COPD patients. However, in contrast to other biomarkers, the relationship appears to be L-shaped (and not linear), suggesting a threshold at approximately 150. While promising, future studies are needed to validate this simple index as a biomarker in COPD.


Subject(s)
Biomarkers/blood , C-Reactive Protein/biosynthesis , Fibronectins/blood , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/mortality , Adult , Female , Follow-Up Studies , Humans , Inflammation , Male , Middle Aged , Proportional Hazards Models , Reproducibility of Results , Treatment Outcome
3.
Br J Clin Pharmacol ; 61(4): 398-404, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16542200

ABSTRACT

AIMS: Spirometry, plethysmography and impulse oscillometry (IOS) measure different aspects of lung function. These methods have not been compared for their ability to assess long- and short-acting anticholinergic agents. We therefore performed a double-blind, placebo-controlled, four-way cross-over study in 30 healthy subjects. METHODS: Single doses of tiotropium bromide (Tio) 54 and 18 mcg, ipratropium bromide (IB) 40 mcg and placebo were administered. Specific conductance (sGaw), total lung capacity (TLC), inspiratory capacity (IC) and residual volume (RV) were measured using plethysmography, while IOS measured resistance (R5-25) and reactance (RF and X5). Pulmonary function was measured for 26 h post dose. RESULTS: Tio caused significant improvements in sGaw, forced expiratory voume in 1 s (FEV(1)), maximum mid-expiratory flow (MMEF) and R5-R25 at time points up to 26 h, with no clear differences between doses. IB improved the same parameters, but only up to 8 h. The weighted mean change (0-24 h) caused by Tio 54 mcg compared with placebo for FEV(1) was 240 ml (95% confidence interval 180, 300), while for sGaw the ratio of geometric means (Tio compared with placebo) was 1.35 (1.28, 1.41). Neither drug caused consistent statistically significant changes in RF, forced vital capacity, TLC or IC over 26 h. RV was significantly improved from 8 to 24 h by Tio 54 mcg only. CONCLUSIONS: In addition to spirometry, IOS resistance measurements and sGaw can distinguish between the effects of long- and shortacting anticholinergic effects in healthy subjects.


Subject(s)
Cholinergic Antagonists/pharmacology , Ipratropium/pharmacology , Lung/drug effects , Oscillometry/methods , Plethysmography/methods , Scopolamine Derivatives/pharmacology , Adult , Airway Resistance/drug effects , Airway Resistance/physiology , Cross-Over Studies , Double-Blind Method , Forced Expiratory Flow Rates/drug effects , Forced Expiratory Flow Rates/physiology , Forced Expiratory Volume/drug effects , Forced Expiratory Volume/physiology , Humans , Lung/physiology , Male , Residual Volume/drug effects , Residual Volume/physiology , Spirometry/methods , Tiotropium Bromide , Total Lung Capacity/drug effects , Total Lung Capacity/physiology
4.
Thorax ; 61(1): 23-8, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16143583

ABSTRACT

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) have raised serum levels of C reactive protein (CRP). This may be related directly to COPD and its associated systemic inflammation or secondary to other factors such as concomitant ischaemic heart disease (IHD) or smoking status. The aim of this study was to evaluate IHD and smoking as potential causes of raised CRP levels in COPD and to test the association between inhaled corticosteroid (ICS) use and serum CRP levels. METHODS: Cross sectional analyses comparing cohorts of 88 patients with COPD, 33 smokers (S), and 38 non-smoker (NS) controls were performed. Clinical assessments included a complete medical history, pulmonary function, 6 minute walk test (6MWT), cardiopulmonary exercise test, and high sensitivity serum CRP measurements. RESULTS: Serum CRP levels were significantly higher in patients with COPD (5.03 (1.51) mg/l) than in controls (adjusted odds ratio 9.51; 95% confidence interval 2.97 to 30.45) but were similar in the two control groups (S: 2.02 (1.04) mg/l; NS: 2.24 (1.04) mg/l). There was no clinical or exercise evidence of unstable IHD in any of the subjects. CRP levels were lower in COPD patients treated with ICS than in those not treated (3.7 (3.0) mg/l v 6.3 (3.6) mg/l); this association was confirmed in an adjusted regression model (p<0.05). CONCLUSION: CRP levels are raised in COPD patients without clinically relevant IHD and independent of cigarette smoking, and reduced in patients with COPD using ICS. CRP may be a systemic marker of the inflammatory process that occurs in patients with COPD.


Subject(s)
C-Reactive Protein/metabolism , Myocardial Ischemia/complications , Pulmonary Disease, Chronic Obstructive/blood , Smoking/blood , Adrenal Cortex Hormones/adverse effects , Case-Control Studies , Exercise Test , Exercise Tolerance/physiology , Female , Forced Expiratory Volume/physiology , Humans , Male , Myocardial Ischemia/blood , Pulmonary Disease, Chronic Obstructive/physiopathology , Smoking/adverse effects , Vital Capacity/physiology
5.
Vaccine ; 19(7-8): 764-78, 2000 Nov 22.
Article in English | MEDLINE | ID: mdl-11115698

ABSTRACT

A DNA vaccine against the hepatitis B virus (HBV) was evaluated for safety and induction of immune responses in 12 healthy, hepatitis-naïve human volunteers using the needle-free PowderJect system to deliver gold particles coated with DNA directly into cells of the skin. Three groups of four volunteers received three administrations of DNA encoding the surface antigen of HBV at one of the three dose levels (1, 2, or 4 microg). The vaccine was safe and well tolerated, causing only transient and mild to moderate responses at the site of administration. HBV-specific antibody and both CD4+ and CD8+ T cell responses were measured before and after each immunization. All the volunteers developed protective antibody responses of at least 10 mIU/ml. In volunteers who were positive for the HLA class I A2 allele, the vaccine also induced antigen-specific CD8+ T cells that bound HLA-A2/HBsAg(335-343) tetramers, secreted IFN-gamma, and lysed target cells presenting a hepatitis B surface antigen (HBsAg) CTL epitope. Enumeration of HBsAg-specific T cells producing cytokine indicated preferential induction of a Type 1 T helper cell response. These results provide the first demonstration of a DNA vaccine inducing protective antibody titers and both humoral and cell-mediated immune responses in humans.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Hepatitis B Antibodies/biosynthesis , Hepatitis B Vaccines/administration & dosage , T-Lymphocytes, Helper-Inducer/immunology , Vaccines, DNA/administration & dosage , Adult , Biolistics , Female , Gold , Hepatitis B/immunology , Hepatitis B/prevention & control , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/adverse effects , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Humans , Male , Middle Aged , Particle Size , Plasmids/genetics , Safety , Vaccines, DNA/adverse effects
6.
Eur J Immunol ; 30(7): 1823-9, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10940871

ABSTRACT

Human memory T lymphocytes have recently been re-defined as central or effector memory cells (Sallusto, F., Lenig, D., Forster, R., Lipp, M. and Lanzavecchia, A., Nature 1999. 401: 708-712). Effector memory cells (T(em)) are targeted to the peripheral tissues and show rapid effector function in response to antigenic stimulation. Central memory (T(cm)) cells are targeted to the lymph nodes and cannot be immediately activated. In this report HLA-A2-Epstein-Barr virus (EBV) peptide tetramers have been used to characterize the EBV-specific CD8+ T cell subsets in persistent EBV infection. In short-term activation studies two populations of tetramer-positive T cells were identified. One group resembled T(em) cells in that they rapidly produced IFN-gamma and lacked the lymph node homing receptor, CD62L, the second was similar to T(cm) cells since they were CD62L+ but could not be immediately induced to express IFN-gamma.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Herpesvirus 4, Human/immunology , Immunologic Memory/immunology , L-Selectin/biosynthesis , Oligopeptides/immunology , Antigens, CD/biosynthesis , Antigens, Differentiation, T-Lymphocyte/biosynthesis , Biomarkers , CD8-Positive T-Lymphocytes/classification , CD8-Positive T-Lymphocytes/drug effects , Cell Membrane/immunology , HLA-A2 Antigen/immunology , Humans , Interferon-gamma/biosynthesis , Lectins, C-Type , Mitogens/pharmacology , T-Lymphocyte Subsets/classification , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/immunology , Tetradecanoylphorbol Acetate/pharmacology
7.
Dev Biol (Basel) ; 104: 115-9, 2000.
Article in English | MEDLINE | ID: mdl-11713809

ABSTRACT

We are developing a DNA vaccine toward hepatitis-B virus (HBV) using PowderJect's proprietary needle-free technology to deliver DNA-coated gold particles directly into cells of the skin. Preclinical studies in animals showed that (i) microgram doses of the DNA vaccine were sufficient to immunize pigs and non-human primates to antibody levels comparable to those obtained with a commercial recombinant subunit vaccine; (ii) the DNA vaccine was effective in mouse strains that respond poorly to protein subunit vaccines; (iii) the vaccine induces robust cytotoxic T-cell responses, and (iv) the vaccine is non-toxic and well tolerated. Based on these findings, this DNA vaccine was evaluated for safety, tolerability, and the induction of immune responses in phase 1 clinical studies in healthy, hepatitis-naïve human volunteers. Preliminary results indicate that the vaccine is safe and well tolerated, and elicits both humoral and cellular immune responses in man.


Subject(s)
Biolistics/methods , Hepatitis B Vaccines/administration & dosage , Vaccines, DNA/administration & dosage , Animals , Biolistics/instrumentation , Drug Tolerance , Haplorhini , Hepatitis B Antibodies/biosynthesis , Hepatitis B Vaccines/adverse effects , Hepatitis B Vaccines/genetics , Hepatitis B Vaccines/immunology , Humans , Swine , T-Lymphocytes, Cytotoxic/immunology , Vaccines, DNA/adverse effects , Vaccines, DNA/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...